MET and neoplasm: Furthermore, by dichotomising patients according to the median expression of c-MET/VEGFR-2 into c-MET/VEGFR-2LOW (≤ median) and c-MET/VEGFR-2HIGH (> median) groups, data showed that patients with c-MET/VEGFR-2HIGH tumours treated with bevacizumab had significantly reduced OS compared to c-MET/VEGFR-2LOW tumours (39.3 vs. > 60 months; multivariable HR 2.00, 95%CI 1.08–3.72, P = 0.03; Fig. 1A) whereas in the placebo group, there was no significant difference (multivariable HR 1.26, 95%CI 0.67–2.39, P = 0.47; Fig. 1B).